Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from CASI Pharmaceuticals ( (CASI) ) is now available.
On December 23, 2025, CASI Pharmaceuticals announced that a Nasdaq Hearings Panel granted the company an extension to remain listed on the Nasdaq Capital Market, provided it regains compliance with the Market Value of Listed Securities requirement by February 17, 2026. The extension, which follows an initial deficiency notice issued on May 5, 2025 and a prior grace period through November 3, 2025, temporarily halts any suspension of CASI’s securities while the company works to restore its market value above the $35 million threshold. The Panel’s decision took into account CASI’s recent strategic moves, including leadership changes, a renewed focus on executing development of CID-103, a convertible note financing, ongoing funding initiatives, and a planned divestiture of its China assets, signaling both operational restructuring and continued pressure to stabilize its financial and market position for investors and other stakeholders.
The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Underperform.
CASI Pharmaceuticals has a low overall stock score due to significant financial challenges, including declining revenue and increasing losses, coupled with bearish technical indicators and poor valuation metrics. The absence of positive earnings call data or corporate events further weighs on the score.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage, public biopharmaceutical company focused on developing CID-103, a fully human, potentially best-in-class anti-CD38 monoclonal antibody for the treatment of organ transplant rejection and autoimmune diseases. The company holds exclusive global rights to CID-103, is conducting and planning Phase 1 clinical trials in renal allograft antibody-mediated rejection in the U.S. and immune thrombocytopenia, and is evaluating technologies to develop a stable, high-concentration subcutaneous formulation.
Average Trading Volume: 112,892
Technical Sentiment Signal: Sell
Current Market Cap: $12.55M
For a thorough assessment of CASI stock, go to TipRanks’ Stock Analysis page.